HDAC-IN-32 is a highly effective HDAC inhibitor presenting IC50 values of 5.2, 11, and 28 nM for HDAC1, HDAC2, and HDAC6, respectively. This compound demonstrates notable anti-proliferative properties against tumor cells, as well as significant in vivo antitumor efficacy, which can elicit antitumor immunity [1].

HDAC-IN-32 (compound 9k) enhances Ac-HH3 and Ac-tubulin expression in tumor cells and induces apoptosis via caspase-3 cleavage. It decreases SSRP1 and SPT16 levels, leading to chromatin damage. Additionally, HDAC-IN-32 surpasses SAHA in inhibiting tumor migration by reducing MMP-2 expression, which is essential for tumor mobility [1].